Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 0.72 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4095140 | 1.00 | PGR (0.72) | PGRNR3C1NR3C2AR | |
| SCHEMBL3517961 | 0.84 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL3521863 | 0.83 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL4094432 | 0.81 | PGR (0.71) | PGRNR3C1NR3C2AR | |
| SCHEMBL4104290 | 0.81 | PGR (0.71) | PGRNR3C1NR3C2AR | |
| SCHEMBL4094429 | 0.81 | PGR (0.71) | PGRNR3C1NR3C2AR | |
| SCHEMBL4104291 | 0.81 | PGR (0.71) | PGRNR3C1NR3C2AR | |
| SCHEMBL7693458 | 0.78 | PGR (0.70) | PGRNR3C1NR3C2AR | |
| SCHEMBL4099929 | 0.76 | PGR (0.72) | PGRNR3C1NR3C2AR | |
| SCHEMBL4099925 | 0.76 | PGR (0.72) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | WYETH LLC (US) | 2012-08-30 | — | — | US | claimed |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | WYETH (US) | 2009-04-16 | — | — | US | claimed |
| US-7115649-B2 | Methods of treating skin disorders using thio-oxindole derivatives | WYETH (US) | 2006-10-03 | — | — | US | claimed |
| EP-1515680-A4 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | WYETH CORP (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1515680-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | Wyeth (US) | 2005-03-23 | — | — | EP | claimed |
| US-20040006122-A1 | Methods of treating skin disorders using thio-oxindole derivatives | WYETH | 2004-01-08 | — | — | US | claimed |
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2004-01-01 | — | — | US | claimed |
| WO-2004000227-A2 | USE OF THIO-OXINDOLE DERIVATIVES IN TREATMENT OF SKIN DISORDERS | WYETH (US) | 2003-12-31 | — | — | WO | claimed |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | WYETH LLC (US) | 2012-08-30 | — | — | US | disclosed |
| US-8242098-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH LLC (US) | 2012-08-14 | — | — | US | disclosed |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | WYETH (US) | 2009-04-16 | — | — | US | disclosed |
| US-7488734-B2 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2009-02-10 | — | — | US | disclosed |
| US-7115649-B2 | Methods of treating skin disorders using thio-oxindole derivatives | WYETH (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040006122-A1 | Methods of treating skin disorders using thio-oxindole derivatives | WYETH | 2004-01-08 | — | — | US | disclosed |
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | WYETH (US) | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002535-A1 | Methods of treating hormone-related conditions using thio-oxindole derivatives | GPER1, OXTR, SHBG | PGR 44/4885NR3C1 121/4885NR3C2 97/4885 |
| US-20040006122-A1 | Methods of treating skin disorders using thio-oxindole derivatives | SRD5A1, SRD5A2, OXER1 | PGR 1297/4885NR3C1 208/4885NR3C2 477/4885 |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | OXTR, GNRHR, SHBG | PGR 23/4885NR3C1 179/4885NR3C2 89/4885 |
| US-20090099223-A1 | METHODS OF TREATING HORMONE-RELATED CONDITIONS USING THIO-OXINDOLE DERIVATIVES | OXTR, GNRHR, SHBG | PGR 23/4885NR3C1 179/4885NR3C2 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.